Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743610 | 0.84 | KMT2A (0.37) | ALDH1A1LMNATP53SMN1; SMN2MEN1 | |
| SCHEMBL6743611 | 0.83 | ALDH1A1 (0.38) | ALDH1A1LMNATP53SMN1; SMN2MEN1 | |
| SCHEMBL28584958 | 0.83 | KMT2A (0.35) | ALDH1A1LMNATP53SMN1; SMN2MEN1 | |
| SCHEMBL155917 | 0.81 | ALOX5 (0.43) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL155916 | 0.81 | ALOX5 (0.43) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL11550667 | 0.79 | ALDH1A1 (0.41) | ALDH1A1LMNATP53SMN1; SMN2MEN1 | |
| SCHEMBL7815263 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL10786707 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL6404489 | 0.78 | ALDH1A1 (0.41) | ALDH1A1LMNACES1ALOX15CA12 | |
| SCHEMBL3239381 | 0.77 | NPSR1 (0.40) | ALDH1A1LMNATP53SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-109456216-A | A kind of no catalyst is reacted without aromatic amine under the conditions of promotor with the amine that turns of amide derivatives | 湘潭大学 | 2019-03-12 | — | — | CN | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-8871782-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| US-8530687-B2 | Catalysts, methods of making catalysts, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2478981-A1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | Sumitomo Chemical Co., Ltd (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120059182-A1 | Catalysts, Methods of Makting Catalysts, and Methods of Use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-0702673-B1 | BENZ(B)AZEPINE-2,5-DIONES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5656626-A | NERVOUS SYSTEM OR BRAIN DISORDERS; BENZ(B)AZEPINE | ZENECA LIMITED (GB) | 1997-08-12 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0705834-A1 | Quinoxaline-2,3-diones with an azaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
| EP-0702673-A1 | BENZ(B)AZEPINE-2,5-DIONES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ZENECA LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5502048-A | CNS, STROKES, HYPOGLYCEMIC AGENTS AND ANTIISCHEMIC AGENTS | ZENECA LIMITED (GB) | 1996-03-26 | — | — | US | disclosed |
| WO-1994029275-A1 | BENZ(B)AZEPINE-2,5-DIONES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ZENECA LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
| EP-0172789-A2 | Process for the sulfation of compounds containing a hydroxyethyl group | CIBA-GEIGY AG (CH) | 1986-02-26 | — | — | EP | disclosed |
| US-4157333-A | CONDENSATION OF 1,2-METHYLENEDIOXYBENZENE WITH N-ALKYLOORMANILIDE, HYDROLYSIS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059182-A1 | Catalysts, Methods of Makting Catalysts, and Methods of Use | DKC1, ADCK1, AMD1 | ALDH1A1 191/4885LMNA 2478/4885TP53 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.